Exelixis Inc. Reports Q1 2025 Revenue Surge to $555.4M; Non-GAAP EPS Climbs to $0.62

Reuters
2025/05/14
Exelixis Inc. Reports Q1 2025 Revenue Surge to $555.4M; Non-GAAP EPS Climbs to $0.62

Exelixis Inc. has released its financial results for the first quarter of 2025, showcasing a notable increase in non-GAAP net income compared to the same period in 2024. The non-GAAP net income for the quarter ended March 31, 2025, was reported at $179.6 million, or $0.64 per share basic and $0.62 per share diluted. This reflects a significant rise from the non-GAAP net income of $52.0 million, or $0.17 per share basic and diluted, reported for the comparable period in 2024. Exelixis has also updated its financial guidance for fiscal year 2025. The company now anticipates total revenues to be in the range of $2.25 billion to $2.35 billion, an increase from the previous guidance of $2.15 billion to $2.25 billion. Similarly, net product revenues are expected to reach between $2.05 billion and $2.15 billion, up from the earlier forecasted range of $1.95 billion to $2.05 billion. These updates reflect Exelixis' ongoing efforts to enhance its financial performance and provide investors with useful supplementary information through the presentation of non-GAAP financial measures. The company continues to utilize these measures to better understand and evaluate its business operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513874586) on May 13, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10